The current testing recommendation is to include HER2 mutation testing upfront as part of broad molecular profiling for NSCLC patients with advanced or metastatic disease, in particular, if approved therapies are available [1, 35]. The gene discussed is ERBB2; the disease is metastatic neoplasm.